|
|
Blood, 1 October 2007, Vol. 110, No. 7, pp. 2316-2323.
Prepublished online as a Blood First Edition Paper on June 20, 2007; DOI 10.1182/blood-2007-02-074641.
 Previous Article | Next Article 
Submitted February 15, 2007
Accepted June 14, 2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial
Andrea Gallamini*, Francesco Zaja, Caterina Patti, Atto Billio, Maria Rosaria Specchia, Alessandra Tucci, Alessandro Levis, Annunziata Manna, Vincenzo Secondo, Luigi Rigacci, Antonello Pinto, Emilio Iannitto, Valerio Zoli, Pierfederico Torchio, Stefano Pileri, and Corrado Tarella
Hematology department, Ospedale S. Croce, Cuneo, Italy
Hematology department, Universita di Udine, Udine, Italy
Hematology Department, Ospedale Cervello, Palermo, Italy
Hematology Department, Ospedale Regionale Generale, Bolzano, Italy
Hematology Department, Ospedale S.Giuseppe Moscati, Taranto, Italy
Hematology Department, Spedali Civili, Brescia, Italy
Hematology Department, Ospedale S. Antonio e Biagio, Alessandria, Italy
Onco Hematology department, Ospedale ASL 5, La Spezia, Italy
Internal Medicine Department, Ospedale Galliera, Genova, Italy
Hematology Chair, Universita di Firenze, Firenze, Italy
Onco-Hematology Unit, Ospedale Pascale, Napoli, Italy
Hematology Chair, Universita di Palermo, Palermo, Italy
Hematology department, Ospedale S. Camillo Forlanini, Roma, Italy
Medical Statistics Chair, Universita di Torino, Torino, Italy
Pathology Chair, Unit of Hemolymphopathology, Universita di Bologna, Bologna, Italy
Hematology Chair, Universita di Torino, Torino, Italy
* Corresponding author; email: gallamini.a{at}ospedale.cuneo.it.
To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the CHOP regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive PTCL patients entered the study and received 8 CHOP courses, Campath was added at 30 mg. s.c. at day -1 initially to the first four courses (four patients), and then to all eight courses (20 patients). CR was achieved in 17 (71%) patients, 1 had partial remission and 6 stable/progressive disease. At a median follow-up of 16 months (5-42), 14 patients are alive, nine had died from progressive disease and one from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effect were grade 4 neutropenia and CMV reactivation. Major infections were J-C virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis and pneumonia. The shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID# 141202.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
H. C. Kluin-Nelemans, J. L. Coenen, J. E. Boers, G. W. van Imhoff, and S. Rosati
EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Blood,
August 15, 2008;
112(4):
1039 - 1041.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Jaeger, F. Bauer, R. Brezinschek, C. Beham-Schmid, C. Mannhalter, and P. Neumeister
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine
Ann. Onc.,
May 1, 2008;
19(5):
1025 - 1026.
[Full Text]
[PDF]
|
|
|
| |
